MX2017004973A - Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7. - Google Patents

Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7.

Info

Publication number
MX2017004973A
MX2017004973A MX2017004973A MX2017004973A MX2017004973A MX 2017004973 A MX2017004973 A MX 2017004973A MX 2017004973 A MX2017004973 A MX 2017004973A MX 2017004973 A MX2017004973 A MX 2017004973A MX 2017004973 A MX2017004973 A MX 2017004973A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating
subject
antisense oligonucleotide
Prior art date
Application number
MX2017004973A
Other languages
English (en)
Inventor
Giovanni Monteleone
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MX2017004973A publication Critical patent/MX2017004973A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

La presente invención se refiere al tratamiento de una enfermedad intestinal inflamatoria (por ejemplo, enfermedad de Crohn y colitis ulcerativa) utilizando nucleótidos antisentido que se dirigen contra formas polimórficas (por ejemplo, aquellas que contienen polimorfismos de de nucleótidos sencillos) del ARNm SMAD7; así, la invención se refiere a métodos de tratamiento para sujetos que tienen formas polimórficas de SMAD7 y oligloneuclótidos antisentido que hacen objetivo específicamente transcripciones de ARNm SMAD7 que contienen polimorfismos.
MX2017004973A 2014-10-17 2015-10-16 Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7. MX2017004973A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462065598P 2014-10-17 2014-10-17
PCT/EP2015/074066 WO2016059239A1 (en) 2014-10-17 2015-10-16 Methods and compositions for treating a subject with a smad7 antisense oligonucleotide

Publications (1)

Publication Number Publication Date
MX2017004973A true MX2017004973A (es) 2017-12-07

Family

ID=54330761

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004973A MX2017004973A (es) 2014-10-17 2015-10-16 Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7.

Country Status (12)

Country Link
US (2) US10337004B2 (es)
EP (1) EP3207136A1 (es)
JP (1) JP2017532961A (es)
KR (1) KR20170069262A (es)
CN (1) CN107406851A (es)
AU (1) AU2015332624A1 (es)
CA (1) CA2964667A1 (es)
EA (1) EA201790867A1 (es)
IL (1) IL251717A0 (es)
MA (1) MA43331A (es)
MX (1) MX2017004973A (es)
WO (1) WO2016059239A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
EP2364360B1 (en) 2008-11-13 2017-03-22 Nogra Pharma Limited Antisense compositions and methods of making and using same
MX350087B (es) 2011-09-15 2017-08-24 Nogra Pharma Ltd Metodos para vigilar la capacidad de respuesta a la terapia anti-smad7.
AU2013249191B2 (en) 2012-04-18 2019-01-03 Nogra Pharma Limited Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
JP2017515896A (ja) 2014-05-09 2017-06-15 ノグラ ファーマ リミテッド 炎症性腸疾患の処置の方法
EP3213070A2 (en) * 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3420082A4 (en) * 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION
WO2018122376A1 (en) * 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1456380T3 (da) 2001-11-02 2012-07-30 Giuliani Int Ltd SMAD7-inhibitorer til behandling af CNS-sygdomme
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
EP2364360B1 (en) 2008-11-13 2017-03-22 Nogra Pharma Limited Antisense compositions and methods of making and using same
WO2010085151A2 (en) * 2009-01-26 2010-07-29 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil
EP2534262B1 (en) * 2010-02-08 2016-12-14 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
MX350087B (es) * 2011-09-15 2017-08-24 Nogra Pharma Ltd Metodos para vigilar la capacidad de respuesta a la terapia anti-smad7.
AU2013249191B2 (en) 2012-04-18 2019-01-03 Nogra Pharma Limited Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
RU2674147C2 (ru) 2013-03-15 2018-12-05 Ногра Фарма Лимитед Способы лечения колоректального рака
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
JP2017515896A (ja) 2014-05-09 2017-06-15 ノグラ ファーマ リミテッド 炎症性腸疾患の処置の方法
EP3213070A2 (en) 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
EP3207135A2 (en) 2014-10-17 2017-08-23 Celgene Alpine Investment Company II, LLC Isotopologues of smad7 antisense oligonucleotides
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
MA41271A (fr) 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
CA3000195A1 (en) 2015-09-30 2017-04-06 Celgene Alpine Investment Company Ii, Llc Tlr modulators and methods of use
EP3355896A2 (en) 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression

Also Published As

Publication number Publication date
EP3207136A1 (en) 2017-08-23
MA43331A (fr) 2017-08-23
WO2016059239A1 (en) 2016-04-21
EA201790867A1 (ru) 2017-08-31
IL251717A0 (en) 2017-06-29
US20190338283A1 (en) 2019-11-07
CA2964667A1 (en) 2016-04-21
AU2015332624A1 (en) 2017-05-04
JP2017532961A (ja) 2017-11-09
KR20170069262A (ko) 2017-06-20
US20170240893A1 (en) 2017-08-24
CN107406851A (zh) 2017-11-28
US10337004B2 (en) 2019-07-02

Similar Documents

Publication Publication Date Title
MX2017004973A (es) Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7.
PH12016502563A1 (en) Substituted nucleosides, nucleotides and analogs thereof
MX2017008184A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
MX2017008183A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
WO2016106401A3 (en) Rna agents for p21 gene modulation
NZ730296A (en) Modified double-stranded rna agents
PH12017500669A1 (en) Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
PH12016500660A1 (en) Substituted nucleosides, nucleotides and analogs thereof
IL295418A (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
EA201791820A1 (ru) Олигонуклеотидная терапия врожденного амавроза лебера
CY1121037T1 (el) Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων
ZA201901061B (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
MD4760B1 (ro) Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D
HK1259060A1 (zh) 抑制腎素原基因或腎素原受體基因表達的單鏈核酸分子及其用途
EA201791986A1 (ru) Олигонуклеотиды, соответствующие экзону 73 гена col7a1, для терапии буллезного эпидермолиза
MX2018001126A (es) Oligonucleotidos terapeuticos.
NZ741841A (en) Antisense oligonucleotides for use in treating alzheimer’s disease
MX2017014855A (es) Oligonucleotidos atisentido para tratar epidermolisis bullosa distrofica.
EP3130597A4 (en) Oligonucleotide having non-natural nucleotide at 5'-terminal thereof
MX2020002110A (es) Composiciones y metodos para detectar y tratar la resistencia a la insulina.
WO2015179660A3 (en) Epigenetic engineering to study the role of aberrant dna methylation in disease
MY175723A (en) Oligonucleotides and a method for detecting and/or quantifying human metapneumovirus (hmpv)
PL410511A1 (pl) Sposób amplifikacji DNA w reakcji łańcuchowej polimerazy w czasie rzeczywistym za pomocą starterów metylo-specyficznych dla promotora genu DCLKI
MY190099A (en) Oligonucleotides and method for detecting and identifying salmonella serotypes causing non-typhoidal salmonellosis